ALDOsterone for Prediction of Post-Operative Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post-operative atrial fibrillation (POAF) is a major and frequent complication occurring after cardiac surgery, contributing to prolonged intensive care and hospital stays and is associated with several cardiovascular complications. The exact mechanisms and signaling pathways involved in the development of POAF seem to be multifactorial and remain to date incompletely understood. β-blockers and amiodarone are the first line preventive drugs but are partially effective and near 30% of POAF resist to these strategies. In this context, there is some evidence indicating that renin-angiotensin-aldosterone system and Galectin-3 (Gal-3) share signaling pathways in the development of cardiac fibrosis and therefore could be very useful predictive biomarkers of POAF and potentially interesting therapeutic target to prevent POAF occurrence.

The investigators hypothesis is that preoperative plasma aldosterone levels and galectin-3 (Gal-3) expression (in plasma, right atrial appendage or epicardial fat) could be predictive of POAF in patients undergoing elective CABG surgery with preserved LVEF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study)

NCT02804321

Atrial Fibrillation Aldosterone

UNKNOWN

Evaluation and Monitoring of the Protocol Post Operative Atrial Fibrillation

NCT05165862

Post Operative Atrial Fibrillation

COMPLETED

A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery

NCT05780320

Atrial Fibrillation New Onset

COMPLETED

Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery

NCT04607122

Atrial Fibrillation Cardiac Surgery

COMPLETED PHASE3

Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery

NCT01570530

Atrial Fibrillation

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Planned cardiac surgery. POAF occurence or not

The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) \< 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients hospitalized for planned surgical coronary revascularization +/- aortic replacement valve
* Aged 18 years at least
* Clinically Stable (see criteria for non-inclusion)
* With left ventricular ejection fraction preserved (\>50%)

Exclusion Criteria

* Patient having already AF history
* Patient with primary hyperaldosteronism
* Unstable Patient defined as any cardiovascular event occurred in the previous 30 days

These events are:

* hospitalisation for cardiovascular causes
* appearance or worsening of symptoms consistent with cardiac failure
* appearance or worsening symptoms of coronary
* Patient refusing participation in the study
* Patient unable to provide follow-up visits
* need for concomitant mitral surgery
* Emergency CABG
* Left ventricular ejection fraction (LVEF) \< 50%
* Previous heart surgery
* Off pump CABG.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No